Researchers evaluated the safety of valiltramiprosate and its associated risk for amyloid-related imaging abnormalities in ...
Morning Overview on MSN
Major review finds limited benefits from new Alzheimer’s drugs hailed as breakthroughs
For the roughly 6.9 million Americans living with Alzheimer’s disease, the arrival of drugs that target amyloid plaques in ...
Researchers have struggled for generations to make any progress in treatments. There have been widespread hopes that drugs like Leqembi and Kisunla, which emerged just a couple of years ago, would ...
Alzheimer’s disease is usually known as a brain condition. Most people think of memory loss, confusion, and changes in ...
Anti-amyloid drugs have been considered game-changing for Alzheimer's, but an extensive review has revealed that the drugs ...
It's the latest in a long-running dispute over the drugs, which some view as groundbreaking, while others say they leave much ...
New Alzheimer's drugs targeting brain amyloid show minimal real-world benefits, a major review found. While plaque reduction ...
Alzheimer’s disease is one of the most common causes of memory loss and dementia in older adults. It slowly damages the brain ...
These drugs were hailed by proponents as breakthroughs in the fight to treat Alzheimer’s disease, but a new independent ...
With innovative approaches to life-threatening diseases and natural disasters, UC San Diego researchers are making critical ...
A systematic review suggested that drugs targeting amyloid beta appeared to have no clinically meaningful positive effects, ...
Anti-amyloid drugs likely provide no "clinically meaningful" effects for people with Alzheimer's, the authors concluded.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results